- URB937
-
- $42.00 / 5mg
-
2026-03-13
- CAS:1357160-72-5
- Min. Order:
- Purity: 99.55%
- Supply Ability: 10g
|
| Product Name: | URB937 | | Synonyms: | URB937;Cyclohexylcarbamic acid 3′–carbamoyl–6–hydroxybiphenyl–3–yl ester;3'-Carbamoyl-6-hydroxybiphenyl-3-yl cyclohexylcarbamate;Carbamic acid, N-cyclohexyl-, 3'-(aminocarbonyl)-6-hydroxy[1,1'-biphenyl]-3-yl ester;3'-Carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate;FAAH,URB 937,Inhibitor,URB937,low,toxicity,inhibit,Fatty acid amide hydrolase,OEA,URB-937;URB937, 10 mM in DMSO;URB937 ，S3586 | | CAS: | 1357160-72-5 | | MF: | C20H22N2O4 | | MW: | 354.4 | | EINECS: | 604-604-1 | | Product Categories: | | | Mol File: | 1357160-72-5.mol |  |
| | URB937 Chemical Properties |
| Boiling point | 562.8±50.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMSO: soluble15mg/mL, clear | | form | powder (1:1 ratio of product to ethanol) | | pka | 9.08±0.50(Predicted) | | color | white to beige | | InChI | 1S/C20H22N2O4/c21-19(24)14-6-4-5-13(11-14)17-12-16(9-10-18(17)23)26-20(25)22-15-7-2-1-3-8-15/h4-6,9-12,15,23H,1-3,7-8H2,(H2,21,24)(H,22,25) | | InChIKey | CMEQHOXCIGFZNJ-UHFFFAOYSA-N | | SMILES | N(C3CCCCC3)C(=O)Oc1cc(c(cc1)O)c2cc(ccc2)C(=O)N |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | URB937 Usage And Synthesis |
| Uses | URB 937 is a potent inhibitor of fatty-acid amide hydrolase (FAAH), an intracellular serine hydrolase responsible for the deactivation of the endocannabinoid anandamide. It is actively extruded from the central nervous system (CNS), and therefore increases anandamide levels exclusively in peripheral tissues. | | Biological Activity | URB937 is a fatty acid amide hydrolase (FAAH) inhibitor th at is actively excluded from the CNS by the membrane transporter ABCG2. The ED50 for inhibition of FAAH activity in the brain is 200 times higher than inhibition of renal FAAH activity. In vivo administration of URB937 elevates anandamide levels in peripheral tissues, and attenuates acetic acid-induced writhing, hyperalgesia in a sciatic nerve ligation model, and pain and edema in carrageenan injected paws. | | in vivo | URB937 (1 mg/kg, i.p.) administrated in mice increases anandamide levels in peripheral tissues, but not forebrain or hypothalamus[1].
URB937 (1 mg/kg, s.c.) suppresses pain responses elicited by i.p. injections of acetic acid[1].
URB937 in male rats (an oral dose 3 mg/kg, F = 36%) is absorbed at a moderate rate and displays a peak plasma concentration (Cmax) of 159.47 ng/ml, which was achieved one hour after administration. URB937 exhibits T1/2 of 60 min by an oral dose of 3 mg/kg[2].
URB937 produces a high degree of antinociception in female mice and rats in models of visceral and inflammatory pain. Moreover, the compound displayed a restricted access to placental and fetal tissues in pregnant mice and rats[3].
URB937 (1 mg/kg, every 2 days for 30 days) attenuates radiation-induced lung injury and increased endocannabinoid concentration in lung tissue[4].
| Animal Model: | Swiss Webster mice[1]. | | Dosage: | 1 mg/kg. | | Administration: | S.C. | | Result: | Suppressesd pain responses elicited by i.p. injections of acetic acid. |
| Animal Model: | Adult Sprague Dawley male and female rats (250-300 g)[2]. | | Dosage: | 0.3, 1, 3, 10 mg/kg (Pharmacokinetic Analysis). | | Administration: | Single oral dose. | | Result: | Inhibited liver FAAH activity with a median effective dose (ED50) of 0.9 mg/kg.
Inhibits FAAH in peripheral tissues and identify a possible biomarker for target engagement.
|
|
| | URB937 Preparation Products And Raw materials |
|